Scotiabank Initiates Coverage On EyePoint Pharmaceuticals with Sector Outperform Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on EyePoint Pharmaceuticals with a Sector Outperform rating and set a price target of $18.
October 16, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank has initiated coverage on EyePoint Pharmaceuticals with a Sector Outperform rating and a price target of $18, indicating a positive outlook.
The initiation of coverage with a Sector Outperform rating and a price target of $18 by Scotiabank suggests a positive outlook for EyePoint Pharmaceuticals. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100